Compare FNWD & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FNWD | MDXH |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.0M | 183.4M |
| IPO Year | N/A | 2021 |
| Metric | FNWD | MDXH |
|---|---|---|
| Price | $37.47 | $3.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $34.00 | $7.67 |
| AVG Volume (30 Days) | 18.5K | ★ 134.6K |
| Earning Date | 01-27-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | $66,245,999.00 | ★ $103,069,000.00 |
| Revenue This Year | $16.40 | $23.34 |
| Revenue Next Year | $5.36 | $22.98 |
| P/E Ratio | $19.66 | ★ N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $26.16 | $1.35 |
| 52 Week High | $39.99 | $5.33 |
| Indicator | FNWD | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 44.64 |
| Support Level | $36.97 | $3.45 |
| Resistance Level | $38.99 | $3.80 |
| Average True Range (ATR) | 0.84 | 0.20 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 64.78 | 5.00 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.